Back to Screener

QIAGEN N.V. (QGEN)

NYSE Mid Cap

Healthcare › Biological Products, (No Diagnostic Substances)

$39.93
Market Cap: $8.7B
Data as of Dec 31, 2025

Price History

Feb 9, 2026 — Apr 4, 2026

Investment Snapshot

  • Trading 44% above Graham Number — above intrinsic value estimate
  • Piotroski F-Score 7/9 — financially strong with improving fundamentals
  • ROE of 11.2% — below-average profitability
  • Revenue growing at 6% annually

QIAGEN N.V. (QGEN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NYSE , with a market capitalisation of $8.7 billion . Key value metrics: P/E ratio 20.4, P/B ratio 2.29, Piotroski F-Score 7 out of 9 (strong financial health) .

Value Score

Key Metrics

P/E Ratio
20.39
2.29
EPS
$1.96
Div. Yield
0.6%
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio

Current vs 5-Year Average

Based on 5 years of SEC filings
Net Margin
↑ +2.1pp avg —
Gross Margin
↑ +2.1pp avg —
Operating Margin
↑ +2.1pp avg —
Return on Equity
↑ +2.1pp avg —
Debt / Equity
↑ +2.1pp avg —

Revenue & Net Income

EPS & Free Cash Flow Per Share

Financial Statements

Metric FY22 FY23 FY24
Revenue $X.XB $X.XB $X.XB
Gross Profit $X.XB $X.XB $X.XB
Operating Income $X.XB $X.XB $X.XB
Net Income $X.XB $X.XB $X.XB
EBITDA $X.XB $X.XB $X.XB
Total Assets $X.XB $X.XB $X.XB
Total Liabilities $X.XB $X.XB $X.XB
Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

QIAGEN N.V. — Fundamental Analysis Summary

QIAGEN N.V. (QGEN) is currently trading 44% above its Graham Number of $27.71, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 20.4x.

On financial health, QGEN shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 11.2% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.44.

StockPik's composite Value Score for QGEN is 91/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

QGEN reports a high gross margin of 62.2% (sector average: 33.5%) and a strong operating margin of 22.3%.

QGEN shows revenue growing at 6% year-over-year, with earnings growing at 408%.

QGEN pays a modest dividend yield of 0.6%.

Top Value Stocks in Healthcare

Symbol Price P/E Score
CYRX $8.21 4.7 100
CRMD $6.70 3.6 100
CGEN $2.06 5.5 100
ABEO $4.82 4.5 100
BDMD $2.01 5.8 100
High Piotroski F-Score stocks
Other stocks with F-Score ≥ 7 showing broad financial improvement
How is the Value Score calculated?
Read our full methodology →
How is the Graham Number calculated?
Benjamin Graham's intrinsic value formula, worked examples, and how to use it →
Previous
QDEL
Next
QH